<DOC>
	<DOCNO>NCT01016951</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability , pharmacokinetics pharmacodynamics inhale AZD9164 follow administration multiple ascend dos healthy male female subject COPD patient .</brief_summary>
	<brief_title>A Multiple Ascending Dose Study With AZD9164 Given 13 Days Healthy Male Female Subjects Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Healthy male female , age 1845 , COPD patient &gt; 40 year Healthy subject COPD patient ; Provision sign date , write informed consent prior study specific procedure Healthy subject ; Females must negative pregnancy test , must lactate must nonchildbearing potential , follow criterion : irreversible surgical sterilisation hysterectomy , bilateral oophorectomy bilateral salpingectomy COPD patient ; Females must negative pregnancy test , must lactate must nonchildbearing potential , follow criterion : Post menopausal . Woman 50 year old consider post menopausal amenorrheic 12 month follow cessation exogenous hormonal treatment , LH FSH level post menopausal range . Women 50 year age consider post menopausal amenorrheic 12 month follow cessation exogenous hormonal treatment . irreversible surgical sterilisation hysterectomy , bilateral oophorectomy bilateral salpingectomy Healthy subject ; Have body mass index ( BMI ) 18 30 kg/m2 inclusive weigh least 50 kg 100 kg COPD patient ; Have body mass index ( BMI ) 18 32 kg/m2 inclusive weigh least 50 kg 100 kg Healthy subject ; Any clinically significant disease disorder , opinion investigator , may either put subject risk participation study , influence result subject 's ability participate study COPD patient ; Any clinically significant disease disorder ( COPD ) , opinion investigator , may either put subject risk participation study , influence result subject 's ability participate study Healthy subject COPD patient ; Any clinically significant abnormality clinical chemistry , haematology , urinalysis physical examination result judge investigator Healthy subject COPD patient ; Any clinically important abnormality rhythm , conduction morphology rest ECG may interfere interpretation QTc interval change</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Safety study</keyword>
	<keyword>AZD9164</keyword>
</DOC>